PharmaRadar360

PharmaRadar360

๐ŸŒยท12h agodiscoveryTier 3 ยท Aggregated media

HLB, Having Surpassed Cholangiocarcinoma, Expected to Resubmit New Liver Cancer Drug Application to FDA Next Month

Publisher

์•„
์•„์‹œ์•„๊ฒฝ์ œ

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the attributed publisher through Google News.

Open via Google News

At a glance

Publisher
์•„์‹œ์•„๊ฒฝ์ œ
Region
Global
Scope
discovery
Published
September 29, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

This record currently routes through Google News. Confirm important claims against the publisher or a primary record.

Source: ์•„์‹œ์•„๊ฒฝ์ œ

Scope: discovery

Evidence: Tier 3 ยท Aggregated media

Open Google News route
HLB, Having Surpassed Cholangiocarcinoma, Expected to Resubmit New Liver Cancer Drug Application to FDA Next Month | PharmaRadar360